About Diasome Pharmaceuticals
Diasome Pharmaceuticals is a private company based in Cleveland, Ohio. It has reported $62,535,117 raised in eight offerings on Form D since April 2009. Its chief executive is Robert Geho.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 2024 | Aug 15, 2024 | $3,090,740of $15.5M target | 4 | $772K | Equity, OptionsRule 506(b) | Form D ↗ |
| Jun 22, 2023 | Jun 30, 2023 | $8,999,998of $14.9M target | 2 | $4.4M | EquityRule 506(b) | Form D ↗ |
| Aug 26, 2022 | Sep 8, 2022 | $16,724,591of $19.0M target | 40 | $418K | EquityRule 506(b) | Form D ↗ |
| Sep 21, 2020 | Dec 23, 2020 | $1,500,000of $5.0M target | 6 | $250K | Debt, OptionsRule 506(b) | Form D ↗ |
| Mar 17, 2020 | Apr 1, 2020 | $2,885,788of $2.8M target | 20 | $144K | EquityRule 506(b) | Form D ↗ |
| Oct 12, 2018 | Oct 26, 2018 | $12,084,000of $18.6M target | 22 | $549K | DebtRule 506(b) | Form D ↗ |
| Dec 16, 2016 | Jan 17, 2017 | $4,350,000of $8.0M target | 4 | $1.0M | DebtRule 506(b) | Form D ↗ |
| Mar 27, 2008 | Apr 13, 2009 | $12,900,000of $13.4M target | 9 | $1.4M | Equity, Debt06 | Form D/A ↗ |
| Total, eight offerings | $62,535,117 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Diasome Pharmaceuticals's Form D filed Aug 15, 2024.
Earlier filings also listed Marc Penn (director, last listed Jun 2023), Richard Caruso (director, last listed Jan 2017), Michele Ollier (director, last listed Jan 2017), Helga Kautsky (executive officer, last listed Jan 2017), Guiseppe Zocco (director, last listed Jan 2017), Len Rosenberg (president and director, last listed Apr 2009), Devang Kantesaria (director, last listed Apr 2009) and Brenda Gavin (director, last listed Apr 2009).